ClinicalTrials.Veeva

Menu
V

Velocity Clinical Research | Syracuse, NY

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Gantenerumab
[18F]PI-2620
RG7774
JNJ-63733657
JNJ-64042056

Parent organization

This site is a part of Velocity Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 6 total trials

[18F]PI-2620 Phase 3 Histopathological Study

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620...

Enrolling
Alzheimer Disease
Drug: [18F]PI-2620

The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main o...

Active, not recruiting
Epstein-Barr Virus Infection
Biological: mRNA-1189
Biological: Placebo

The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheime...

Active, not recruiting
Alzheimer Disease
Cognitive Dysfunction
Drug: JNJ-63733657
Drug: Placebo

The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Comp...

Active, not recruiting
Preclinical Alzheimer's Disease
Drug: JNJ-64042056
Drug: Placebo

Trial sponsors

Roche logo
Janssen (J&J Innovative Medicine) logo
Janssen (J&J Innovative Medicine) logo
L
Moderna logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems